Additional insights should be gained from ongoing randomized phase III trial of proton versus photon SBRT in HCC patients (NCT03186898), which will investigate plasma HGF as an integrated biomarker for susceptibility to RILD. This evidence concerns the gene HGF and hepatocellular carcinoma.